Dihydroergotamine, ergotamine, methysergide and sumatriptan - Basic science in relation to migraine treatment

Headache

Volumn 52, Issue 4, 2012, Pages 707-714

  Dahlöf, Carl ^a   Maassen Van Den Brink, Antoinette ^b  

^a Gothenburg Migraine Clinic   (Sweden)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

ergotamine; headache; migraine; sumatriptan

Indexed keywords

2 [[2 (DIMETHYLAMINO)ETHYL]THIO] 3 PHENYLQUINOLINE; BROMOCRIPTINE; CAFFEINE; CAFFEINE PLUS ERGOTAMINE TARTRATE; CYPROHEPTADINE; CYTOCHROME P450 3A4; DEXAMETHASONE; DIHYDROERGOTAMINE; DOPAMINE RECEPTOR; DRUG METABOLITE; ERGOTAMINE; ERYTHROMYCIN; ETHINYLESTRADIOL; KETANSERIN; KETOCONAZOLE; METHYSERGIDE; MIANSERIN; NIFEDIPINE; OMEPRAZOLE; SERGOLEXOLE; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 1F RECEPTOR; SEROTONIN RECEPTOR; SUMATRIPTAN; VERAPAMIL;

ANUS PRURITUS; ARTERIOSCLEROSIS; BINDING AFFINITY; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CELLULITIS; COLD; CORONARY ARTERY SPASM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG FORMULATION; DRUG METABOLISM; DRUG TOLERABILITY; FOOT PAIN; GANGRENE; HEART INFARCTION; HOT FLUSH; HUMAN; HYPERTENSION; INJECTION SITE BURNING; INJECTION SITE STINGING; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LEG PAIN; LIVER DISEASE; LUNG FIBROSIS; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; NAUSEA; PARESTHESIA; PEPTIC ULCER; PERIPHERAL VASCULAR DISEASE; PLEURAL FIBROSIS; PREGNANCY; PRIORITY JOURNAL; RETROPERITONEAL FIBROSIS; REVIEW; SIDE EFFECT; SILENT MYOCARDIAL ISCHEMIA; SKIN TINGLING; TASTE DISORDER; THROMBOPHLEBITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSIENT ISCHEMIC ATTACK; UTERUS CONTRACTION; VALVULAR HEART DISEASE; VASCULAR HEADACHE; VOMITING; WEAKNESS;

ANIMALS; DIHYDROERGOTAMINE; ERGOTAMINE; HUMANS; METHYSERGIDE; MIGRAINE DISORDERS; SUMATRIPTAN; TREATMENT OUTCOME;

EID: 84859731823     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2012.02124.x     Document Type: Review

References (70)

1. Villalõn CM, Centuriõn D,. Cardiovascular responses produced by 5-hydroxytriptamine: A pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn-Schmiedebergs Arch Pharmacol. 2007; 376: 45-63.
2. Barnes NM, Andrade R, Bockaert J, et al,. 5-Hydroxytryptamine receptors, introductory chapter. IUPHAR database (IUPHAR-DB). Available at:. Accessed March 5, 2012.
3. Peroutka SJ, Howell TA,. The molecular evolution of G protein-coupled receptors: Focus on 5-hydroxytryptamine receptors. Neuropharmacology. 1994; 33: 319-324.
4. Hargreaves RJ, Shepheard SL,. Pathophysiology of migraine-new insights. Can J Neurol Sci. 1999; 26 (Suppl. 3): S12-S19.
5. Peroutka SJ, Havlik S, Oksenberg D,. Wolff Award presentation 1993. Anti-migraine drug interactions with cloned human 5-hydroxytryptamine1 receptor subtypes. Headache. 1993; 33: 347-350.
6. Tfelt-Hansen P, De Vries P, Saxena PR,. Triptans in migraine: A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000; 60: 1259-1287.
7. van den Broek RW, Bhalla P, VanDenBrink AM, de Vries R, Sharma HS, Saxena PR,. Characterization of sumatriptan-induced contractions in human isolated blood vessels using selective 5-HT(1B) and 5-HT(1D) receptor antagonists and in situ hybridization. Cephalalgia. 2002; 22: 83-93.
8. Silberstein SD, Hargreaves RJ,. The history and pharmacology of ergotamine and dihydroergotamine. In:, Diener HC, ed. Drug Treatment of Migraine and Other Frequent Headaches. Basel: Karger Press; 2000: 52-65.
9. Tfelt-Hansen P, Saxena PR,. 5-HT receptor antagonists in migraine prophylaxis. In:, Diener HC, ed. Drug Treatment of Migraine and Other Frequent Headaches. Basel: Karger Press; 2000: 279-287.
10. Silberstein SD, McCrory DC,. Ergotamine and dihydroergotamine: History, pharmacology, and efficacy. Headache. 2003; 43: 144-166.
11. Müller-Schweinitzer E,. Ergot alkaloids in migraine: It the effect via 5-HT receptors? In:, Olesen J, Saxena PR, eds. 5-Hydroxytryptamine Mechanisms in Primary Headaches. New York, NY: Raven; 1992: 297-304.
12. Müller-Schweinitzer E, Weidmann H,. Basic pharmacological properties. In:, Berde B, Schild HO, eds. Ergot Alkaloids and Related Compounds. Berlin, Heidelberg, New York, NY: Springer Verlag; 1978: 87-232.
13. 1-adrenoceptors mediate the external carotid vasoconstriction to ergotamine in vagosympathectomised dogs. Naunyn-Schmiedebergs Arch Pharmacol. 2004; 370: 46-53.
14. 2-adrenoceptors. Br J Pharmacol. 1999; 126: 585-594.
15. Cortijo J, Marti-Cabrera M, Bernabeu E, et al,. Characterization of 5-HT receptors on human pulmonary artery and vein: Functional and binding studies. Br J Pharmacol. 1997; 122: 1455-1463.
16. Ostergaard JR, Mikkelsen E, Voldby B,. Effects of 5-hydroxytryptamine and ergotamine on human superficial temporal artery. Cephalalgia. 1981; 1: 223-228.
17. MaassenVanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR,. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation. 1998; 98: 25-30.
18. Silberstein SD,. The pharmacology of ergotamine and dihydroergotamine. Headache. 1997; 37 (Suppl. 1): S15-S25.
19. Andersen AR, Tfelt-Hansen P, Lassen NA,. The effect of ergotamine and dihydroergotamine on cerebral blood flow in man. Stroke. 1987; 18: 120-123.
20. Tfelt-Hansen P,. The effect of ergotamine on the arterial system in man. Acta Pharmacol Toxicol (Copenh). 1986; 59 (Suppl. 3): 1-30.
21. Tfelt-Hansen P, Kanstrup IL, Christensen NJ, Winkler K,. General and regional haemodynamic effects of intravenous ergotamine in man. Clin Sci. 1983; 65: 599-604.
22. 1D receptor agonist effects of dihydroergotamine. In:, Olesen J, Moskowitz MA, eds. Experimental Headache Models. Philadelphia, PA: Lippincott-Raven; 1995: 163-167.
23. Tfelt-Hansen P, Paalzow L,. Intramuscular ergotamine: Plasma levels and dynamic activity. Clin Pharmacol Ther. 1985; 37: 29-35.
24. De Hoon JN, Poppe KA, Thijssen HH, Struijker-Boudier HA, Van Bortel LM,. Dihydroergotamine: Discrepancy between arterial, arteriolar and pharmacokinetic data. Br J Clin Pharmacol. 2001; 52: 45-51.
25. Saper JR, Silberstein S,. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache. 2006; 46 (Suppl. 4): S171-S181.
26. Silberstein SD, Young WB,. Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Working Panel of the Headache and Facial Pain Section of the American Academy of Neurology. Neurology. 1995; 45: 577-584.
27. Hoskin KL, Kaube H, Goadsby PJ,. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study. Brain. 1996; 119: 249-256.
28. Saxena PR, Den Boer MO,. Pharmacology of antimigraine drugs. J Neurol. 1991; 238 (Suppl. 1): S28-S35.
29. 1-like agonists in the treatment of migraine. J Neurol. 1991; 238 (Suppl. 1): S57-S61.
30. 2Breceptor agonism in cardiac valvular fibrosis. Clin Neuropharmacol. 2006; 29: 80-86.
31. Silberstein SD,. Methysergide. Cephalalgia. 1998; 18: 421-435.
32. Dahlöf C,. Integrating the triptans into clinical practice. Curr Opin Neurol. 2002; 15: 317-322.
33. Dahlöf CG,. Non-oral formulations of triptans and their use in acute migraine. Curr Pain Headache Rep. 2005; 9: 206-212.
34. Linde M, Mellberg A, Dahlöf C,. Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack. Cephalalgia. 2006; 26: 113-121.
35. Dahlöf CGH, Diener H-C,. Migraine-an endemic disease inside the blood-brain-barrier. Future Neurol. 2009; 4: 405-420.
36. de Vries B, Frants RR, Ferrari MD, van den Maagdenberg AM,. Molecular genetics of migraine. Hum Genet. 2009; 126: 115-132.
37. Edvinsson L,. Tracing neural connections to pain pathways with relevance to primary headaches. Cephalalgia. 2011; 31: 737-747.
38. Borsook D, Burstein R, Becerra L,. Functional imaging of the human trigeminal system: Opportunities for new insights into pain processing in health and disease. J Neurobiol. 2004; 61: 107-125.
39. Borsook D, Burstein R, Moulton E, Becerra L,. Functional imaging of the trigeminal system: Applications to migraine pathophysiology. Headache. 2006; 46 (Suppl. 1): S32-S38.
40. Buzzi MG, Moskowitz MA,. The trigemino-vascular system and migraine. Pathol Biol (Paris). 1992; 40: 313-317.
41. Goadsby PJ, Edvinsson L, Ekman R,. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988; 23: 193-196.
42. Zimmermann K, Reeh PW, Averbeck B,. ATP can enhance the proton-induced CGRP release through P2Y receptors and secondary PGE(2) release in isolated rat dura mater. Pain. 2002; 97: 259-265.
43. Zimmermann K, Reeh PW, Averbeck B,. S+ -flurbiprofen but not 5-HT1 agonists suppress basal and stimulated CGRP and PGE2 release from isolated rat dura mater. Pain. 2003; 103: 313-320.
44. Xiao Y, Richter JA, Hurley JH,. Release of glutamate and CGRP from trigeminal ganglion neurons: Role of calcium channels and 5-HT1 receptor signaling. Mol Pain. 2008; 4: 12 Abstract.
45. Jenkins DW, Langmead CJ, Parsons AA, Strijbos PJ,. Regulation of calcitonin gene-related peptide release from rat trigeminal nucleus caudalis slices in vitro. Neurosci Lett. 2004; 366: 241-244.
46. Lance JW,. The pathophysiology of migraine. Ann Acad Med Singapore. 1985; 14: 4-11.
47. Dahlöf CG,. Sumatriptan: Pharmacological basis and clinical results. Curr Med Res Opin. 2001; 17 (Suppl. 1): s35-s45.
48. Goadsby PJ,. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med. 2007; 13: 39-44.
49. Moskowitz MA, Cutrer FM,. Sumatriptan: A receptor-targeted treatment for migraine. Annu Rev Med. 1993; 44: 145-154.
50. Shields KG, Goadsby PJ,. Serotonin receptors modulate trigeminovascular responses in ventroposteromedial nucleus of thalamus: A migraine target? Neurobiol Dis. 2006; 23: 491-501.
51. 1 recognition sites. J Recept Res. 1988; 8: 59-81.
52. Leysen JE,. Serotonergic binding sites. In:, Vanhoutte PM, ed. Serotonin and the Cardiovascular System. New York, NY: Raven Press; 1985: 43-62.
53. Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C,. Dihydroergotamine-erythromycin-induced ergotism. Ann Intern Med. 1988; 109: 249 Abstract.
54. Christians U, Schmidt G, Bader A, et al,. Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol. 1996; 41: 187-190.
55. Aurora SK, Silberstein SD, Kori SH, et al,. MAP0004, orally inhaled DHE: A randomized, controlled study in the acute treatment of migraine. Headache. 2011; 51: 507-517.
56. Sanders SW, Haering N, Mosberg H, Jaeger H,. Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing. Eur J Clin Pharmacol. 1986; 30: 331-334.
57. Ibraheem JJ, Paalzow L, Tfelt-Hansen P,. Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers. Br J Clin Pharmacol. 1983; 16: 695-699.
58. Perrin VL,. Clinical pharmacokinetics of ergotamine in migraine and cluster headache. Clin Pharmacokinet. 1985; 10: 334-352.
59. Banhidy F, Acs N, Puho E, Czeizel AE,. Ergotamine treatment during pregnancy and a higher rate of low birthweight and preterm birth. Br J Clin Pharmacol. 2007; 64: 510-516.
60. Connor HE,. Sumatriptan-pharmacology. In:, Diener HC, ed. Drug Treatment of Migraine and Other Frequent Headaches. Basel: Karger Press; 2000: 83-92.
61. Kallen B, Lygner PE,. Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. Headache. 2001; 41 (4): 351-356.
62. 1D agonist, in patients with acute migraine. Cephalalgia. 2001; 21: 727-732.
63. 1F receptor agonist lasmiditan-a randomised proof-of-concept trial. Cephalalgia. 2010; 30: 1170-1178.
64. Sheftell FD, Dahlöf CG, Brandes JL, Agosti R, Jones MW, Barrett PS,. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. Clin Ther. 2005; 27: 407-417.
65. Kallen B, Nilsson E, Otterblad Olausson P. Delivery outcome after maternal use of drugs for migraine Drug Saf. 2011; 34 (8): 691-703.
66. Dodick D, Lipton RB, Martin V, et al,. Consensus statement: Cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004; 44: 414-425.
67. Valentgas P, Cole A, Mo J, et al,. Triptan use is not associated with increased risk of severe vascular events in migraine patients. Eur J Neurol. 2002;(Suppl 2): 45.
68. Hall GC, Brown MM, Mo J, et al,. Migraine, triptan treatment and the risk of cardiovascular disease, stroke and mortality. Eur J Neurol. 2002; 9 (Suppl. 2): 150.
69. Cassina M, Di Gianantonio E, Toldo I, Battistella PA, Clementi M,. Migraine therapy during pregnancy and lactation. Expert Opin Drug Saf. 2010; 9: 937-948.
70. Humphrey PPA,. 5-Hydroxytryptamine and the pathophysiology of migraine. J Neurol. 1991; 238 (Suppl. 1): S38-S44.